Correspondence 0001104659-23-081208 from GridAI Technologies Corp. (GRDX)

GridAI Technologies Corp.
Date: July 14, 2023 · CIK: 0001604191 · Accession: 0001104659-23-081208

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-272404

Date

July 14, 2023

Author

James Sapirstein

Form

CORRESP

Company

GridAI Technologies Corp.

Letter

Re: First Wave BioPharma, Inc. (the “Company”)

July 14, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Withdrawal of Acceleration Request - Registration Statement on Form S-1 (File No. 333-272404)

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on July 12, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for July 13, 2023, at 5:00 p.m., Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

Please call John D. Hogoboom of Lowenstein Sandler LLP at 973-597-2382 with any questions.

Very truly yours,
FIRST WAVE BIOPHARMA, INC.

Show Raw Text

CORRESP
1
filename1.htm

July 14, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    First Wave BioPharma, Inc. (the “Company”)

    Withdrawal of Acceleration Request - Registration Statement on Form S-1 (File No. 333-272404)

Ladies and Gentlemen:

Reference is made to our letter,
filed as correspondence via EDGAR on July 12, 2023, in which we requested the acceleration of the effective date of the above-referenced
Registration Statement for July 13, 2023, at 5:00 p.m., Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as
amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw
our request for acceleration of the effective date.

Please call John D. Hogoboom
of Lowenstein Sandler LLP at 973-597-2382 with any questions.

    Very truly yours,

    FIRST WAVE BIOPHARMA, INC.

    By:
    /s/ James Sapirstein

    Name:
    James Sapirstein

    Title:
    Chief Executive Officer

SecProbe.io